Immunic receives notice of allowance for composition-of-matter patent of a specific polymorph of vidofludimus calcium in the united states

– patent will also cover a related method of production of the material – – fourth u.s. patent directed to use of vidofludimus calcium in multiple sclerosis – – multilayered intellectual property strategy provides protection into 2041 in the united states and into 2039 internationally, unless extended further – new york, march 20, 2024 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a notice of allowance from the united states patent and trademark office (uspto) for patent application 16/981,122, entitled, "calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents," covering the composition-of-matter of a specific polymorph of vidofludimus calcium (imu-838) and a related method of production of the material. the claims are expected to provide protection into 2039, unless extended further.
IMUX Ratings Summary
IMUX Quant Ranking